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 The optimum hydroxyethyl starch (HES) concentration 
and colloid osmotic (oncotic) pressure were determined for 
lung preservation. The lungs of twenty-five mongrel dogs 
were isolated and flushed with one of four different solutions 
and stored at 4-6 °C for 24 hours. The lungs of each group were 
flushed and cold-stored as follows: Group 1 with Modified-
Collins (CM) solution (n=6); Group 2, CM + 3 % HES 
(n=6); Group 3, CM +6 % HES (n=8); Group 4, CM + 9 % 
HES (n=5). After the hypothermic period, the isolated left 
lung was reperfused for 120 min. 
 During reperfusion, the airway pressure (AWP) in Group 
4 was significantly lower than in Groups 1 or 3. Static lung 
compliance (Cst) in Groups 2 and 4 was apparently higher 
than that in Group 1. Pulmonary vascular resistance (PVR) 
in Group 4 was significantly lower than in Group 1 through-
out the reperfusion period. 
 The wet to dry ratios (W/D) before perfusion in Group 1 
(6.52±0.55) and in Group 2 (6.05±0.74) were significantly 
higher than before preservation (5.19±0.21). The W/Ds after 
reperfusion in Group 3 (6.82±0.78) and Group 4 (7.04±1.22) 
were significantly lower than that in Group 1 (9.40±2.09). 
 In conclusion, a hyperoncotic solution which contains a 
high concentration of HES is useful for hypothermic canine 
lung preservation because it prevents pulmonary edema 
during both preservation and reperfusion periods.
INTRODUCTION 
 The University of Wisconsin (UW) solution has been 
found to preserve effectively in vitro the lungs of experi-
mental animals')-'), and has been applied widely in clinical 
kidney', pancreas' 8) and liver") transplantation. 
 The UW solution contains the colloid HES (hydroxyethyl 
starch), which exerts colloid osmotic (oncotic) pressure 
and prevents interstitial edema's)") and endothelial 
damage 12). Recently, however, it was reported that HES 
can be eliminated from the UW solution without detriment 
in the cold storage of kidneys and livers")-"). However, a 
higher concentration of oncotic agents in the flush-out and 
cold-storage solutions may be required to prevent fluid 
from entering the alveolar space"). 
 In the present study, the efficacy of HES was evaluated
and determined its optimum concentration for lung 
preservation in the isolated lung perfusion model'). 
MATERIALS AND METHODS 
 Twenty-five adult mongrel dogs weighing 8-13 kg were 
anesthetized with intravenous pentobarbital (0.5 ml/kg of 
body weight) and intubated. The dogs were ventilated with 
100 % oxygen using a Harvard ventilator set at a tidal 
volume of 35 ml/(kg of body weight) and a rate of 14 
cycles/min. Median sternotomy was performed, 5000 units 
of heparin sodium was administered intravenously, and 
both lungs were removed en block with the heart. A 
poly-ethylene canula was secured in the main pulmonary 
artery. A 9.0 mm cuffed endotracheal tube was inserted 
through the trachea and ventilated with room air at the 
same volume and rate. The lungs were flushed with 500 ml 
of one of four different solutions at 4-6°C through the 
main pulmonary artery. The mean PA flush pressure was 
monitored continuously and the flush time was recorded. 
Then, both lungs were inflated with room air to end-tidal 
volume, placed in a plastic box filled with each solution, 
and stored in a refrigerator at 4-6 °C for 24 hours. 
 The mongrel dogs were assigned to one of four groups 
which differed in the flush solution used. In Group 1 
(n=6), lungs were flushed with modified-Collins solution 
(ROUSSEL MORISHITA CO., LTD. OSAKA JAPAN), in 
Group 2 (n=6) with Modified-Collins solution + 3 % 
Hydroxyethyl starch (AJINOMOTO CO., INC. TOKYO), 
in Group 3 (n=8) with Modified-Collins solution + 6 % 
Hydroxyethyl starch, and in Group 4 (n=5) with 
Modified-Collins solution + 9 % Hydroxyethyl starch. 
One mM allopurinol and 3mM glutathione, the same 
concentrations used in the UW solution, were added to 
each solution as oxygen free radical scavengers. 
 There was no significant difference in the concenration 
of potassium (85.6 ± 4.5 mmol/1) or sodium (18.4 ± 4.4 
mmol/1) or pH (7.29±0.06 at room temperature) among 
the four experimental solutions. The viscosity of each 
solution was 1.35 ± 0.04 cp in Group 1, 2.28 ± 0.13 cp in
Group 2, 4.30 ± 0.03 cp in Group 3, and 6.34 ± 0.05 cp in 
Group 4. 
 After a hypothermic period, the right main pulmonary 
artery and right main bronchus were ligated to isolate the 
left lung. The isolated left lung was reperfused for 120 
min. An arterial canula was connected to a circuit contain-
ing a reservoir primed with fresh allogeneic blood which 
had been drawn from a femoral vessel and stored in 
citrate-phosphate-dextrose. The number of white blood 
cells in the perfusate was counted before and during the 
reperfusion period. The pulmonary vein was left open so as 
to allow the lung perfusion to drain freely into the reser-
voir. The left lung was ventilated with room air at a tidal 
volume of 20 ml/kg of body weight and a rate of 10 cycles 
/min. The perfusion was pumped continuously with a 
roller pump and maintained at 37 °C in a small 
temperature-controlled bath. A small cannula within the 
pulmonary artery and bronchial cannula were connected to 
pressure transducers and a recorder permitted continuous 
monitoring of pulmonary arterial pressure (PAP) and 
airway pressure (AWP). The flow rate was measured with 
a pneumotachograph. Pulmonary venous pressure was set 
at 0 mmHg by adjusting the height of the apex of the 
lungs. The pulmonary flow rate was maintained at 10 ml/ 
kg/min. Pulmonary vascular resistance (PVR) was calcu-
lated as pulmonary arterial pressure/flow rate (mmHg/1/ 
min), and static lung compliance (Cst, effective lung 
compliance) as flow rate/pressure (ml/cmH2O), at 1.2 
seconds into the end-inspiratory plateau. Blood gas analy-
sis of the pulmonary venous perfusate was performed. 
Lungs were weighed before perfusion (after preservation 
for 24 hours) and after reperfusion. Then, the lungs were 
placed in a desiccator at 160 °C for 48 hours after which 
they were again weighed. The wet to dry ratio (W/D) was 
calculated as the wet lung weight divided by the dry lung 
weight. 
  The data were compared among the groups using the 
unpaired -Wilcoxon test. Any p-value of less than 0.05 was 
considered significant.
Table 1. Pulmonary Flush Parameters (mean ±SD) 
 Mean Pulmonary flush pressure (MFP) increases as the 
HES concentration rises, however there was no significant 
difference in MFP between groups 3 and 4. Flush time 
increased as the HES concentration rose.
                 Mean Flush Flush 
               Pressure(MFP) Time 
                (mmHg) (min) 
    CM 3.67 18.0 
 (group 1) ±0.68 ±3.5 
CM +HES3% 4.92 26.5 
 (group 2) ±1.11 ±3.6 
CM +HES6% 6.80 35.3 
 (group 3) ±0.91 ±6.5 
CM +HES9% 5.88 53.7 
 (group 4) ±1.52 ±7.0 
                 group I vs 2 p<0 .05 group I vs 2,3,4 
                 group 1 vs 3 group 2 vs 3,4 p<0.01 
                group 2 vs 4 p<0.01 group 3 vs 4 
                                     Footnotes 
                          CM: Modified-Collins solution 
                          IIES: Ilydroxyethyl Starch
Fig 1. Airway Pressure (AWP) during Reperfusion 
 The AWP in group 4 was significantly lower than in group 
1 or 3 after 60,90, and 120 min of reperfusion.
RESULTS 
 The white blood cell count in every group decreased 
significantly after several minutes of reperfusion and 
remained at the same level throughout the reperfusion 
period. The PaO2 did not differ significantly among the 
four groups. Mean pulmonary flush pressures (MFP) and 
flush times in each group are shown in Table 1. The MFP 
in Group 2 was significantly higher than in Group 1. There 
was no significant difference in MFP between Groups 3 
and 4, and Group 3 had a significantly higher MFP than 
did Group 1 (p<0.05) or Group 2 (p<0.01). The MFP in 
Group 4 was significantly higher than that in Group 1. The 
flush time in Group 2 was significantly longer than in
Group 1, and that in Group 3 was also significantly longer 
than in Group 2. The flush time in Group 4 was 53.7±7.0 
min, which was significantly longer than in the other three 
groups (vs Groups 1, 2, 3; p<0.01). The flush times in the 
four groups increased as the HES concentration was 
increased. 
 The airway pressures (AWP) in each group are shown in 
Fig.1. The AWP in Group 4 was significantly lower than in 
Group 1 or 3 after 60, 90 and 120 min of reperfusion 
(p<0.05), and was lower, but not significantly, than in 
Group 2 after 60, 90 and 120 min. Static lung compliance 
(Cst) in every group decreased gradually (Fig.2). In 
Groups 2 and 4, however, it was apparently higher than 
that in Group 1, after 90 and 120 min of reperfusion 
(p<0.05). In Group 3, it was insignificantly lower than in
Fig 2. Static Lung Compliance (Cst) during Reperfusion 
 Cst in every group decreased gradually. In groups 2 and 4, 
it was significantly higher than that in group 1, after 90 and 
120 min of reperfusion.
Fig 4. Wet to Dry Ratio before parfusion 
 The W/Ds in groups 1 and 2 were significantly higher than 
that before preservation. The W/D in groups 3 and 4 did not 
differ from that before preservation.
Fig 3. Pulmonary Vascular Resistance (PVR) during Re-
perfusion 
 The PVR in group 4 was significantly lower than in group 
1 throughout the reperfusion periods. The PVR in groups 2 
and 3 were also lower than that in group 1.
Fig 5. Wet to Dry Ratio (Postperfusion) 
 The W/Ds in groups 3 and 4 were significantly lower than 
that in group 1. There was no significant difference in W/D 
between groups 3 and 4.
Groups 2 and 4 after 30, 60, 90, and 120 min. The change in 
pulmonary vascular resistance (PVR) for each group is 
shown in Fig.3. The PVR in Group 4 was significantly 
lower than in Group 1 throughout the reperfusion period 
(after 0, 30, 60, 90, and 120 min; p<0.01), and was 
insignificantly lower than that in Groups 2 and 3. The 
PVR in Groups 2 and 3 was lower than that in Group 1 
(Group 2 vs 1; after 0, 30, 90 and 120 min, p<0.05; and 
after 60 min, p<0.01; Group 3 vs 1; p<0.05). The wet to 
dry ratio (W/D) before perfusion (after preservation for 
24 fours) in each group is shown in Fig.4. Before preserva-
tion (just after harvest), the W/D was 5.19±0.21. Before 
perfusion in Group 1 (6.52 ± 0.55) and Group 2 (6.05 ± 
0.74), the W/Ds were significantly higher than that before 
preservation (Group 1, p<0.01; Group 2, p<0.05). The
W/Ds of Group 3 (5.13 ± 0.79) and Group 4 (5.08 ± 0.31) 
was significantly lower than in Group 1 (vs Group 3, 
p<0.01; vs Group 4, p<0.01) and Group 2 (vs Group 3, 
p<0.05; vs Group 4, p<0.01) and did not differ signifi-
cantly from that before preservation. 
 After reperfusion, the W/D in Group 3 (6.82±0.78) was 
significantly (p<0.01) lower than that in Group 1 (9.40 
±2..09) and did not differ apparently from Group 2 (7.73 
±1.42). After reperfusion the W/D in Group 4 was 7.04 
± 1.22, and was obviously lower than in Group 1 (p<0.05). 
This W/D was insignificantly lower than in Group 2 and 
did not differ apparently from that in Group 3.
DISCUSSION 
 We reported previously that the University of Wisconsin 
(UW) solution is useful for hypothermic canine lung 
preservation in an isolated lung perfusion model'). The 
purpose of the present study is to determine the efficacy of 
HES, which is contained in the UW solution, and to 
determine its optimum concentration and colloid osmotic 
(oncotic) pressure in a lung preservation solution using the 
same model. 
 The UW solution, which has been applied widely in 
clinical kidney'), pancreas')'), and liver") transplantation, 
contains a number of important components. Lacto-
bionate is an impermeable anion with a large molecular 
mass which can prevent cell swelling. Glutathione is 
necessary for hypothermic preservation and reperfusion of 
kidney and liver") because it preserves the ability of the 
cells to regenerate ATP and maintain their membrane 
integrity. Allopurinol is an inhibitor of xanthine oxidase 
which has been used to reduce reperfusion injury in grafts 
subjected to prolonged storage by diminishing free radical 
generation 20) 
. 
 Recently, it was reported that the use of the colloid HES 
(hydroxyethyl starch) was questioned and it was proposed 
that HES could be eliminated from the UW solution 
without any detriment to cold storage of the kidney and 
liver 
 It is hypothesized that the colloid osmotic pressure 
(COP) exerted by HES prevents interstitial edema and 
endothelial damage in lung preservation during cold 
storage. The oncotic pressure exerted by the colloid pre-
vents leakage of fluid into the interstitial space by coun-
teracting the intravascular pressure. Another beneficial 
effect of a colloid may be to protect endothelial structure 
and prevent directly hypothermia induced cell swelling"). 
HES (Hydroxyethyl starch) is derived from amylo-
pectin, a branched polysaccharide polymer substituted 
with hydroxyethyl groups at carbons 2, 3, and 6 of the 
glucose ring by reaction with ethylene oxide'). HES may 
have a smaller effect on coagulation and carry a lower risk 
of inducing an anaphylactic reaction than any other 
synthetic colloids, such as dextran, and has been used 
safely to expand volume"). 
 The movement of fluid across the endothelium is gov-
erned by "Starling's equation: 
         Q=K [(Pc-Pi)-P(COPp-COPi)] 
where Q is the net flow out of capillary, K is the filtration 
coefficient, Pc and Pi are the hydrostatic pressures in the 
capillary and interstitial space, respectively, COPp and 
COPT are the corresponding colloid osmotic pressures, and 
P is the reflection coefficient'). Some studies have shown 
that the mean plasma colloid osmotic pressure (COPp) of 
healthy volunteers varies from 19.1 to 27.8 mmHg27>28>. The 
critical minimum COPp is 15-20mmHg, below which 
pulmonary edema will occur"). During ex vivo lung
preservation, pulmonary edema will also occur, if the COP 
in the alveolar capillary becomes lower than that i n the 
interstitial space. 
 Arita and associates reported that the Modified-Collins-
HES solution is a useful initial "wash-out solution" for 
preserving the pancreas, liver or kidney 12). This solution 
contains 6% HES, which creates a colloid osmotic pressure 
of 23.9 mmHg. The COP of this solution nearly equals that 
of normal plasma and prevents interstitial edema during 
the preservation period. We believe that colloid isotonic or 
colloid hypertonic (hyperoncotic) preservation solutions 
are more effective for lung preservation because they 
prevent pulmonary edema during the flushing and preser-
vation periods. This study was undertaken to determine 
the efficacy of HES and to determine its optimum concen-
tration and colloid osmotic pressure in a lung preservation 
solution. 
 In the present study, the W/D before perfusion (after 
preservation for 24 hours) in Groups 1 and 2 were signifi-
cantly higher than that before preservation. During 
preservation, pulmonary edema may have occured in 
Groups 1 and 2. The COP of both solutions were thought to 
be below the normal plasma colloid osmotic pressure. The 
W/D before perfusion in Groups 3 and 4 were the same as 
that before preservation. We feared that the lung weight 
might be decreased as a result of hypovolemia during 
preservation in the colloid hypertonic (hyperoncotic) 
solution, but significant weight loss was not found in 
Group 4. It is suggested that colloid isotonic and 
hypertonic preservation solutions are advantageous 
because they prevent pulmonary edema during the preser-
vation period. 
 MFP increases and flush time is prolonged as the HES 
concentration rises. This may be a result of the increased 
viscosity of the solution, which contains a high concentra-
tion of HES. In this study, the viscosity of each solution 
correlated well with the concentration of HES (R= 
0.9849). Oka and associates described a similar phenome-
non using the UW solution'), which contains 5% HES. High 
pressures and long flush times are common problems 
encountered with hyperoncotic solutions. However, the 
peak flushing pressure in Group 4 was 7 to 8 mmHg and 
was not high enough to damage the alveolar capillary 
membrane or endothelium. Therefore, we do not regard as 
serious the flushing pressure problem. Moreover, colloid 
hypertonic (hyperoncotic) preservation solution may wash 
out RBCs with less volume than do other solutions. 
Adequate RBC washout during the initial cooling flush has 
been suggested to be a determinant of preservation solu-
tion efficacy"). 
 In the present study, airway pressure was not elevated 
and static lung compliance did not decrease in lungs stored 
in a hyperoncotic preservation solution (Group 4). In 
contrast, airway pressure was elevated and static lung 
compliance decreased in lungs stored using HES-free
solutions (Group 1). From the AWP and Cst parameters, 
the solutions containing HES were thought to be useful 
even though their optimum HES concentrations could not 
be determined. Pulmonary vascular resistance was lowest 
in Group 4 from just after the start of reperfusion. A 
hyperoncotic solution may preserve the structure of the 
intra-capillary space by keeping water in the vascular 
compartment and, thereby, reduce pulmonary vascular 
resistance during reperfusion. Dextran 40, the colloid 
contained in low-potassium dextran (LPD) solution, 
exerts potentially beneficial effect by coating endothelial 
surfaces and platelets"). HES may have an effect similar 
to dextran, in reducing vascular resistance despite there 
being a high potassium level in the modified-Collins 
solution. In human heart preservation, it is known that the 
UW solution distributes uniformly throughout the 
myocardium 33). This uniformity of distribution may be 
related to the property of HES that it keeps water in the 
intravascular compartment and, thereby, improves the 
microcirculation. With respect to pulmonary vascular 
resistance, hyperoncotic solution was found to be the most 
useful of the four experimental solutions. 
 In conclusion, the efficacy of the colloid, HES, was 
demonstrated and the hyperoncotic solution was found to 
be preferred for hypothermic canine lung preservation. The 
colloid isotonic and hypertonic (hyperoncotic) solutions 
prevented pulmonary edema for 24 hours during preserva-
tion and during the early stage of reperfusion. No signifi-
cant elevation of AWP or decrease of Cst was observed and 
the lowest PVR was found in lungs preserved with 
hyperoncotic solution. 
 Further study is necessary to determine the most opti-
mum HES concentration and colloid osmotic pressure for a 
lung preservation solution, but the optimum concentration 
and COP may differ in each organ and the species.
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